Dallas, Texas 03/21/2014 (FINANCIALSTRENDS) – Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has following its secondary offering in the first week of March, coming to terms with the sales. While the prices had dropped following the announcement of the second offering, it appears to have made up by the time of the actual sales. This has also led to some positive commentary by analysts across the sectors.
Issues price target revision
Aegis has been the first to be pro-active on Ampio Pharmaceuticals Inc (NYSEMKT:AMPE). The analyst has chosen to move the price target it had set earlier – $15.00 to $16.00.
Following the revision in the price target, Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) was found to see moving high on the trading platform the following day. The prices moved higher by over 5.14%, closing the price per share at $6.56.
Biopharma with development-stage expertise
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) which is pharmaceutical company engaged in production of development-stage products has been in the midst of several activities in the past few quarters.
With a market cap of $341.09million, the company has posted an EPS of -0.62. It currently holds outstanding shares of 51.92 million shares. The company also holds a one-year trading price point at its highest point at $10.86 and low point of $3.95. The company also holds an infra-day trading point of $6.45 low and $6.75 low. at the opening of the previous trading session, the stock prices opened at 6.56.
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has been making some excellent stock market moves in the past few weeks. The latest is the second offering it offered. The company has completed the sale of 9.775 million shares of its common stock, with the transaction valued at $63.3 million.
AMPE now has a well-stocked inventory as well as the funds to move rapidly forward, believe analysts, currently covering this pharmaceutical major.